Kenvue Q3 2026 Earnings: Self Care Leads Growth as Margins Expand

Kenvue (NYSE: KVUE) reported fiscal Q3 2026 net sales of $3.886 billion, up 3.2% year over year, while diluted EPS rose 5% to $0.22 from $0.21. For the quarter ended September 27, organic sales grew 2.9%, led by Self Care, while productivity and cost actions supported margin expansion and nine-month free cash flow increased to $1.6 billion.

Core Financial Results

Sales growth was primarily organic: the 3.2% reported increase consisted of 2.9% organic growth and a 0.3% foreign-currency benefit. Organic growth was balanced between a 1.6% volume increase and 1.3% favorable value realization.

Profit increased faster than sales at the operating level, helped by supply-chain productivity, restructuring and other cost actions. However, the higher effective tax rate limited the resulting growth in net income and EPS.

Adjusted figures are non-GAAP measures and exclude specified items including restructuring, separation-related and pending-transaction costs.

Business and Segment Performance

Self Care was the main growth engine, while Skin Health and Beauty was nearly flat on a reported basis and declined organically. Essential Health delivered growth across all regions, supported more by volume than pricing or mix.

Self Care benefited from favorable inventory comparisons in Asia-Pacific, rising flu incidence in the region and commercial execution behind products including Motrin, Nicorette and Pepcid. U.S. consumption trends improved sequentially, and Tylenol gained market share despite lower seasonal incidence and continued category softness.

Skin Health and Beauty remained the weak point. Distribution losses and the timing of U.S. promotions, along with retailer negotiations in Europe, outweighed growth in Hair Care. Rogaine recorded a fourth consecutive quarter of market-share gains, while OGX maintained momentum.

Essential Health grew in every region. Baby Care, Women’s Health and Wound Care contributed, supported by product launches, distribution expansion and retailer activity involving brands such as Johnson’s Baby, Stayfree, o.b. and BAND-AID.

Margin Expansion Outpaced EPS Growth as the Tax Rate Rose

Gross margin benefited from global supply-chain productivity, U.S. tariff refunds and favorable value realization. Inflation and unfavorable transactional foreign exchange partially offset those gains.

Operating margins also benefited from cost optimization under the 2026 Restructuring Initiative and Our Vue Forward. Quarterly restructuring expense declined to $33 million from $84 million, although Kenvue increased brand support year over year. The company still expects approximately $250 million of pretax restructuring expenses and other charges for fiscal 2026.

Operating income rose approximately 12.2%, but net income increased about 8% and diluted EPS rose 5%. The main constraint was the GAAP effective tax rate, which increased to 29.4% from 24.3% because favorable discrete return-to-provision adjustments were smaller than in the prior year. The adjusted tax rate also rose, to 24.7% from 24.0%. Net interest expense declined modestly to $89 million from $93 million.

Cash Flow and Balance Sheet

Cash-flow figures cover the fiscal nine months ended September 27, 2026, rather than the third quarter alone. Operating cash flow increased to $1.9 billion from $1.3 billion, driven by higher net income and a lower use of working capital. Capital expenditures declined to $0.3 billion from $0.4 billion, lifting non-GAAP free cash flow to $1.6 billion from $1.0 billion.

Kenvue ended the period with $1.0 billion in cash and cash equivalents, compared with $1.1 billion on December 28, 2025. Total debt declined to $8.2 billion from $8.5 billion over the same period.

Management’s View

CEO Kirk Perry attributed the quarter’s performance to disciplined execution, productivity programs and continued investment in brands and innovation. Management said the business transformation launched in the prior year remained on track and also highlighted the pending combination with Kimberly-Clark.

Because of that pending transaction, Kenvue did not provide forward-looking guidance and did not hold a quarterly conference call.

Recent Insider Transactions

The supplied insider data reports purchases of 251,874 shares across nine transactions and sales of 42,191 shares across two transactions during the last six months, resulting in net purchases of 209,683 shares. However, the most recent detailed entries were dominated by stock awards rather than open-market purchases, so the transaction types should be distinguished when interpreting the aggregate data.

The supplied data did not disclose transaction types or values for three other recent entries involving Michael Wondrasch, Meredith Stevens and Anindya Dasgupta. No conclusion about management’s outlook can be drawn solely from the awards or sales listed above.

Risks Investors Need to Watch

• Skin Health and Beauty weakness: Organic sales declined as volume fell 1.7%. Continued U.S. distribution losses, promotion timing issues or prolonged retailer negotiations in Europe could constrain companywide growth.
• Margin benefits may not fully persist: Productivity, tariff refunds and pricing supported margins this quarter, but inflation, transactional currency pressure and higher brand spending remained offsets.
• Restructuring execution: Kenvue expects approximately $250 million of pretax restructuring and related charges in fiscal 2026. The financial benefit depends on successfully simplifying operations and transforming the supply chain.
• Transaction-related uncertainty: The pending Kimberly-Clark combination could create disruption or unanticipated costs. The absence of quantitative guidance and a quarterly conference call also limits visibility into near-term expectations.

Summary

Kenvue’s fiscal third quarter combined organic growth with wider margins and improved year-to-date cash generation. Self Care and Essential Health drove the sales increase, while Skin Health and Beauty remained the principal operating weakness. Investors’ next areas of focus are whether the company can sustain productivity-led margin gains, restore organic growth in beauty and skin care, execute its restructuring plan and manage the pending Kimberly-Clark transaction.